Search clinical trials for: Pegylated Interferon alpha-2a

Total 911 results

Vir Biotechnology, Inc.
Alnylam Pharmaceuticals

Active, not recruiting

Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection

Chronic Hepatitis B

Australia, Hong Kong, Korea, Republic of, Malaysia, New Zealand, Thailand
University Hospital Tuebingen
Dermatologic Cooperative Oncology Group

Completed

Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB

Melanoma

Germany
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C

Chronic Hepatitis C

Taiwan
The Wistar Institute
National Institute of Allergy and Infectious Diseases (NIAID); Hoffmann-La... and other collaborators

Completed

Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection

HIV Infections

United States
BioGeneric Pharma
Xiamen Amoytop Biotech Co., Ltd.

Unknown

Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C

Hepatitis C | Self Efficacy

Egypt
Huashan Hospital

Unknown

Switch or Sequential Combination Therapy of Peginterferon in Hepatitis B Patients With Longterm Entecavir Therapy

Chronic Hepatitis B

China
National Taiwan University Hospital
National Science Council, Taiwan

Completed

Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C

Hepatitis C

Taiwan
King Abdulaziz Medical City

Completed

Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4

Chronic Hepatitis C Virus

Saudi Arabia
Seoul National University Hospital
Roche Pharma AG; SciClone Pharmaceuticals

Completed

Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of
Arbutus Biopharma Corporation

Active, not recruiting

Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection

Chronic Hepatitis b

United States, Korea, Republic of, Hong Kong, Taiwan, Australia, Moldova, Republic of, Ukraine
M.D. Anderson Cancer Center

Completed

Pegasys® in Patients With Myeloproliferative Diseases

Myeloproliferative Disorders

United States
Yonsei University

Completed

A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon

Chronic Hepatitis B

Korea, Republic of
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer

Breast Cancer | Metastatic Cancer

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People

HIV Infections

United States
Hanyang University
Roche Pharma AG

Unknown

Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B. (POTENT)

Hepatitis B, Chronic

Korea, Republic of
Kaohsiung Medical University Chung-Ho Memorial...

Completed

A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients

Chronic Hepatitis C | Genotype

Taiwan
PV-Nord

Completed

Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera

Polycythemia Vera

France
Chinese University of Hong Kong
Hoffmann-La Roche

Completed

Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment

Chronic Hepatitis B

China
José Antonio Carrion
Instituto de Salud Carlos III

Completed

HBsAg Loss Adding Pegylated Interferon in HBeAg-negative Patients

Chronic Hepatitis B (HBeAg-negative)
Bristol-Myers Squibb

Withdrawn

Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C

Hepatitis C Virus (HCV)

India, Korea, Republic of, Poland, Taiwan, Spain, Canada, Russian Federation, Colombia, Singapore, Netherlands, Ireland, United Kingdom, Czech Republic, Hungary, Romania, Hong Kong, Turkey, United States, China, Egypt
ANRS, Emerging Infectious Diseases
Roche Pharma AG

Unknown

A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B (PEGAN)

Chronic Hepatitis B | AgHbs Negativation

France
Amr Hafez
Ain Shams University

Completed

Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4

Hepatitis C
Hoffmann-La Roche

Terminated

An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure

Hepatitis C, Chronic

Romania
Replicor Inc.

Completed

Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B

Hepatitis B, Chronic
Sociedad Andaluza de Enfermedades Infecciosas

Completed

Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients (SAEI_IFN_1)

HIV Infections | Hepatitis C, Chronic

Spain
Hoffmann-La Roche

Completed

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

Renal Cell Carcinoma | Chronic Myelogenous Leukemia | Malignant Melanoma

Canada, India, Bulgaria, Russian Federation, Spain, South Africa, Slovakia
Merck Sharp & Dohme LLC

Terminated

A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)

Hepatitis B, Chronic
Emory University
CURE Childhood Cancer, Inc.

Completed

Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

Juvenile Pilocytic Astrocytomas | Optic Pathway Gliomas

United States
Tehran University of Medical Sciences
Pars No Tarkib Co

Completed

Pegaferon and Ribavirin for Hepatitis C

Hepatitis C

Iran, Islamic Republic of
Tehran Hepatitis Center
Kermanshah University of Medical Sciences

Completed

Effectiveness and Side Effects of Pegylated Interferon Alpha-2a (Pegaferon®) Plus Ribavirin in the Patients With Chronic Hepatitis C

Hepatitis C

Iran, Islamic Republic of
John Mascarenhas
Roche Pharma AG; The Leukemia and Lymphoma Society

Completed

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Polycythemia Vera | Essential Thrombocythemia

United States
Beijing Ditan Hospital

Completed

HBsAg Clearance in Inactive Chronic HBsAg Carriers After Interferon Treated

Chronic Hepatitis B

China
University of Utah

Recruiting

Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis (ATIOM)

Myelofibrosis

United States
Janssen-Cilag International NV

Completed

An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1) (INSIGHT)

Chronic Hepatitis C

Australia, France, United Kingdom, Spain, Russian Federation, Brazil, Poland, Sweden
Replicor Inc.

Completed

REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection

Chronic HBV Infection (HBeAg Negative)

Moldova, Republic of
Federico II University

Withdrawn

24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C

Chronic Hepatitis C

Italy
French National Agency for Research on AIDS and...
Hoffmann-La Roche

Completed

Efficacy of Pegylated Interferon Alone in Egyptian Patients With Acute Hepatitis C (ANRS 1213)

Hepatitis C

Egypt
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 (PRINCIPAL)

Hepatitis C Virus (HCV)

Australia, Belgium, France, Italy, Japan, Korea, Republic of, Mexico, Russian Federation, Taiwan, United States, Chile, Hong Kong, Argentina, Netherlands, United Kingdom, Singapore, New Zealand, Finland, Greece
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Peripheral Blood Mononuclear Cell (PBMC) Gene Expression in HCV Genotype 1 Patients (PBMC)

Chronic Hepatitis C

Taiwan
Johannes Gutenberg University Mainz
Roche Pharma AG

Completed

Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen (PADD-ON)

Chronic Hepatitis B

Germany
Centre hospitalier de l'Université de Montréal...
Hoffmann-La Roche; Centre de Recherche du Centre Hospitalier de l'Université...

Completed

Ribavirin Dose Optimization for the Treatment of Hepatitis C

Chronic Hepatitis C

Canada
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)

Hepatitis C

Taiwan
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection

Acute Hepatitis C

Taiwan
Hoffmann-La Roche

Completed

The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE) (IMPROVE)

Hepatitis C, Chronic

Canada, United States
Janssen-Cilag International NV

Completed

Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C

Genotype 1 Chronic Hepatitis C

Russian Federation
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

Genotype 1 Chronic Hepatitis C | Treatment Naive

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Spain, Sweden, Brazil, Austria, Ireland, Mexico
Tibotec BVBA

Completed

An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection

Hepatitis C
National Taiwan University Hospital
National Science Council, Taiwan; Department of Health, Executive Yuan, R.O...

Completed

Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin

Hemodialysis | Chronic Hepatitis C

Taiwan
Thomas Stauffer Larsen

Completed

A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms (DALIAH)

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia

Denmark
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas

Brain and Central Nervous System Tumors

United States

3

Subscribe